4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

H.C. Wainwright initiated coverage of Upstream Bio with a rating of Buy and set a new price target of $36.00

Evercore ISI downgraded Upstream Bio from Outperform to In-line and set a new price target of $15.00

Mizuho initiated coverage of Upstream Bio with a rating of Outperform and set a new price target of $51.00

Evercore ISI initiated coverage of Upstream Bio with a rating of Outperform and set a new price target of $40.00

Truist initiated coverage of Upstream Bio with a rating of Buy and set a new price target of $47.00

Piper Sandler initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $75.00

JP Morgan initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $38.00

William Blair initiated coverage of Upstream Bio with a rating of Outperform

TD Cowen initiated coverage of Upstream Bio with a rating of Buy

SCHEDULE 13G/A - Upstream Bio, Inc. (0002022626) (Subject)

10-Q - Upstream Bio, Inc. (0002022626) (Filer)

8-K - Upstream Bio, Inc. (0002022626) (Filer)

DEFA14A - Upstream Bio, Inc. (0002022626) (Filer)

DEF 14A - Upstream Bio, Inc. (0002022626) (Filer)

8-K - Upstream Bio, Inc. (0002022626) (Filer)

424B5 - Upstream Bio, Inc. (0002022626) (Filer)

S-8 - Upstream Bio, Inc. (0002022626) (Filer)

10-K - Upstream Bio, Inc. (0002022626) (Filer)

8-K - Upstream Bio, Inc. (0002022626) (Filer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

4 - Upstream Bio, Inc. (0002022626) (Issuer)

WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that additional data from its Phase 2 VIBRANT trial of verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented in an oral session at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 Congress in Istanbul, Turkey, on Sunday, June 14, 2026. The presentation will feature a responder analysis examining the proportion of patients who achieved clinically meaningful improvements in key measures of disease with verek

WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 10:40 a.m. ET. A live webcast of the presentation will be available under the Events tab on the Investors section of Upstream Bio's website on the day of the event. A replay will be available on the Company's website following the presentation. About Upstream BioUpstream

– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and comorbid asthma – – Verekitug led to improvements in nasal polyp score (NPS) in participants with and without comorbid asthma, as well as rapid and sustained reductions in blood and nasal type 2 inflammatory biomarkers – WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented new data from the Phase 2 VIBRANT trial evaluatin

– Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in severe asthma and CRSwNP – – End-of-Phase 2 meetings with FDA planned for mid-2026; Phase 3 initiations in both indications expected in Q1 2027 – – Phase 2 VENTURE trial in COPD ongoing; Company to cap further enrollment; data now expected in the second half of 2027 – – Upcoming data presentations at ATS and EAACI to further elaborate the clinical profile of verekitug – WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirato

WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc.  (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced two upcoming poster presentations at the American Thoracic Society (ATS) 2026 International Conference in Orlando, FL, on Monday, May 18, 2026. The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only known antagonist to the thymic stromal lymphopoietin (TSLP) receptor currently in clinical development, in chronic rhinosinusitis with nasal polyps (CRSwNP). The data to be presented include the clinical effect of verekitug in

– Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen in broad patient populations in both severe asthma and CRSwNP – – Company plans to initiate dosing in Phase 3 trials in both severe asthma and CRSwNP in Q1 2027 – – Reported positive top-line results from Phase 2 VALIANT trial of verekitug in patients with severe asthma in February 2026, demonstrating significant improvements in asthma exacerbations and lung function – – Presented additional analyses from Phase 2 VIBRANT trial at AAAAI, reinforcing verekitug's therapeutic potential in CRSwNP – – Strong cash position of $341.5 million expected to fund planned oper

– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also provided strong efficacy data in new analyses, including reduction in nasal congestion score (NCS) by -0.96 (p < 0.0001) – WALTHAM, Mass., March 01, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented additional data from the Phase 2 VIBRANT clinical trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps (CRSwNP). The

WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care Conference, Boston, MAWednesday, March 4, 2026, Fireside Chat - 9:50 a.m. ET2026 Leerink Partners Global Healthcare Conference, Miami, FLMonday, March 9, 2026, Fireside Chat - 1:40 p.m. ET Live webcasts of the presentations will be available under the Events tab on the Investors section o

– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also delivered clinically meaningful improvements in lung function (FEV1) and exhaled nitric oxide (FeNO) with both dose regimens – – Verekitug was generally well tolerated, with a safety profile consistent with prior studies – – Over 90% of eligible patients have rolled over to the Phase 2 VALOUR long-term extension study – – Upstream Bio to advance verekitug into Phase 3 trials in severe asthma and CRSwNP following planned regulatory interactions – – Management will host a live webcast today at 8:00

WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line results from the Phase 2 VALIANT trial of verekitug, the only known antagonist currently in clinical development that targets and inhibits the thymic stromal lymphopoietin (TSLP) receptor, on Wednesday, February 11, 2026 at 8:00 a.m. ET. The VALIANT trial (NCT06196879) is a Phase 2 global, randomized, double-blind, placebo-controlled, dose-ranging, parallel group clinical trial that evaluated the safety and efficacy of verekitug for up to 60

WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer. Ms. Price brings over 25 years of experience in technical operations, manufacturing, and product development in the biotechnology industry, across a variety of drug modalities. In this role, Ms. Price will oversee the expansion of technical operations and product development in support of Upstream Bio's global development of verekitug, with a focus on chemistry, manufacturing, and controls (CMC) pr

WALTHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company has appointed Allison Ambrose, J.D. as General Counsel. Ms. Ambrose is a senior legal leader with more than 15 years of experience providing counsel on a wide range of matters including corporate governance, securities law and compliance, and capital markets and corporate development transactions. Ms. Ambrose will oversee all aspects of Upstream's legal function and join the Company's executive leadership team. "I am thrilled to welcome Allison to

– In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in placebo-adjusted endoscopic nasal polyp score (NPS) of -1.8 (p<0.0001) – – Significant and clinically meaningful improvements were observed in key secondary endpoints, including -0.8 (p=0.0003) reduction in nasal congestion score and 76% (p=0.03) reduction in need for surgery or systemic corticosteroids – – No serious adverse events (SAEs) observed; generally well tolerated safety profile consistent with previous studies – – Observed clinical effect on endoscopic NPS in this Phase 2 trial suggests verekit

WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line data from the Phase 2 VIBRANT trial of verekitug, the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), on Tuesday, September 2, 2025. The VIBRANT trial (NCT06164704) was a Phase 2 global, randomized, placebo-controlled, parallel group clinical trial designed to assess the efficacy and safety of verekitug in adults with CRSwNP. Participants received either 100 mg of verekitug or pl

SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

SC 13D - Upstream Bio, Inc. (0002022626) (Subject)

SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

SC 13D - Upstream Bio, Inc. (0002022626) (Subject)